Bayer and Janssen pay $775m to settle Xarelto misinformation claimsBMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l1413 (Published 27 March 2019) Cite this as: BMJ 2019;364:l1413
- Owen Dyer
The German drug maker Bayer and the Johnson & Johnson subsidiary Janssen Pharmaceuticals will jointly pay $775m (£587m; €687m) to settle more than 25 000 lawsuits in US federal and state courts, representing almost all of the outstanding claims against the bestselling anticoagulant rivaroxaban (Xarelto).
Janssen holds a licence to sell rivaroxaban in the United States, while Bayer developed the blood thinner and sells it elsewhere.
Neither company admitted liability, and both expressed their continuing confidence in rivaroxaban, which still sells robustly around the world. Bayer’s revenue from the drug last year was $4.07bn, and Janssen’s rivaroxaban sales totalled $2.47bn.
Bayer said that it “continues to believe these claims …